ARE TUMORAL MARKERS PREDICTIVE FACTORS FOR MOLECULAR SUBTYPES IN BREAST CANCER?

  • V. Munteanu The University Emergency Hospital of Bucharest, Department of Oncology
  • Georgiana Radu University of Medicine and Pharmacy “Carol Davila” Bucharest, Romania
  • Monica Cirstoiu The University Emergency Hospital of Bucharest, Department of Oncology; The University of Medicine and Pharmacy „Carol Davila”, Bucharest
Keywords: breast cancer, molecular subtypes, luminal A, luminal B, HER2

Abstract

Breast cancer kills more women annually than any other type of neoplasm. Even though he has shown a particular interest in the medical body since ancient times, the very heterogeneous nature of the tumors and their versatility have made it difficult to find a diagnostic and therapeutic consensus that fully characterizes this pathology and describes its evolution. Immunohistochemical methods manage to outline a gene-molecular profile depending on the biomarkers expressed by each tumor. Correlations between clinical aspects and molecular characteristics of tumors are of particular importance in the management of such a case. The study examined the impact of breast cancer molecular subtypes on therapeutic management for a group of 438 patients treated on the Oncology Department of the Bucharest University Emergency Hospital during 2007-2017.

Published
2019-01-30
How to Cite
[1]
V. Munteanu, G. Radu, and M. Cirstoiu, “ARE TUMORAL MARKERS PREDICTIVE FACTORS FOR MOLECULAR SUBTYPES IN BREAST CANCER?”, JSS, vol. 5, no. 4, pp. 189-194, Jan. 2019.
Section
Articles